Evaluating the Clinical Effectiveness and Safety of Semaglutide in Individuals with Uncontrolled Type 2 Diabetes. Real-World Evidence from Saudi Arabia: The Observational, Multicenter, 15-Month EVOLUTION Study

被引：6

作者：

Alsheikh, Abdulrahman ^{[1
,2
]}

Alshehri, Ali ^{[3
]}

Alzahrani, Saad ^{[3
]}

Jammah, Anwar A. ^{[4
,5
]}

Alqahtani, Fahad ^{[6
]}

Alotaibi, Metib ^{[5
,7
]}

Aldahash, Raed ^{[7
,8
]}

Alhozali, Amani M. ^{[1
,9
]}

Alsabaan, Fahad ^{[10
]}

Almehthel, Mohammed ^{[3
]}

Aljuhani, Naser ^{[11
]}

Aldabeis, Ali ^{[10
]}

Alamri, Moneer ^{[12
]}

Maghawry, Waleed ^{[13
]}

Alzaman, Naweed ^{[14
,15
]}

Alshaikh, Alshaima ^{[16
]}

M. Alnozha, Omar ^{[14
,17
]}

Issak, Emad R. ^{[18
]}

Alsifri, Saud ^{[19
]}

机构：

[1] King Abdulaziz Univ Hosp, Jeddah, Saudi Arabia

[2] Dr Suliman Fakeeh Hosp, Jeddah, Saudi Arabia

[3] King Fahad Med City, Riyadh, Saudi Arabia

[4] King Saud Univ Med City, Riyadh, Saudi Arabia

[5] Alhammadi Hosp, Riyadh, Saudi Arabia

[6] Tadawi Med Ctr, Abha, Saudi Arabia

[7] Dr Suliman Alhabeeb Hosp, Riyadh, Saudi Arabia

[8] King Abdallah Med City, Natl Guard, Riyadh, Saudi Arabia

[9] Int Med Ctr, Jeddah, Saudi Arabia

[10] Secur Forces Hosp, Riyadh, Saudi Arabia

[11] East Jeddah Hosp, Jeddah, Saudi Arabia

[12] Southern Armed Forces Hosp, Khamis Mushait, Saudi Arabia

[13] Alnahda Polyclin, Jeddah, Saudi Arabia

[14] Taibah Univ, Coll Med, Dept Med, Madinah, Saudi Arabia

[15] Madina Med Ctr, Madinah, Saudi Arabia

[16] King Abdallah Med City, Natl Guard, Jeddah, Saudi Arabia

[17] Saudi German Hosp, Madinah, Saudi Arabia

[18] Ain Shams Univ, Dept Internal Med, Cairo, Egypt

[19] Alhada Armed Forces Hosp, Taif, Saudi Arabia

来源：

DIABETES THERAPY | 2024年 / 15卷 / 02期

关键词：

Semaglutide; Type; 2; diabetes; HbA1c; Hypoglycemia; Weight reduction; ONCE-WEEKLY SEMAGLUTIDE; OPEN-LABEL; PHASE; 3A; ADD-ON; EFFICACY; METFORMIN; 56-WEEK;

D O I：

10.1007/s13300-023-01516-z

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: This study aimed to assess the safety and effectiveness of semaglutide, administered either by weekly subcutaneous (SC) injection or orally, in real-life practice in Saudi Arabia in individuals with type 2 diabetes mellitus (T2DM).Methods: A retrospective chart review study was conducted at 18 Saudi Arabia centers. An accredited centralized institutional review board approved the study. Medical records were included for individuals of any age >= 18 years with uncontrolled T2DM. The primary outcome measure was the laboratory glycated hemoglobin (HbA1c) level. Secondary measures included fasting blood glucose (FBG), weight, and hypoglycemia. All variables were checked after 6 and 12 months of semaglutide initiation.Results: The analysis of this study included 1223 patients with uncontrolled T2DM (HbA1c > 7%). The mean (SD) baseline HbA1c was 10.02% (1.17). HbA1c was reduced by an average of 3.02% (0.84) and 3.17% (0.84) at 6 and 12 months, respectively. Results of a repeated measure analysis of variance (ANOVA) indicated significant differences in HbA1c (p value < 0.001). HbA1c levels at 6 and 12 months were significantly lower, 7.00% (0.70) and 6.85% (0.69), than at baseline, 10.02% (1.17). About 193 patients (56.4%) of the 295 patients having HbA1c < 9% achieved HbA1c of 5.7% or less. The frequency of hypoglycemia events was 4.60 (1.10) in the 3 months before semaglutide was initiated. The frequency of hypoglycemia events in the last 3 months was 2.30 (0.80) events and 0.80 (0.50) events at 6-month and 12-month follow-up visits, respectively.The percent reduction in body mass index (BMI) was an average of 13.07% (1.53) and 19.89% (4.07) at 6 and 12 months, respectively. Lipid profile and blood pressure were improved at 6 and 12 months.Conclusion: Semaglutide, administered either by SC injection or orally, provided substantial glycemic and weight-loss benefits in adults with T2DM.

引用

页码：473 / 485

页数：13

共 37 条

[1] Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial [J].

Ahmann, Andrew J. ;

Capehorn, Matthew ;

Charpentier, Guillaume ;

Dotta, Francesco ;

Henkel, Elena ;

Lingvay, Ildiko ;

Holst, Anders G. ;

Annett, Miriam P. ;

Aroda, Vanita R. .

DIABETES CARE, 2018, 41 (02) :258-266

[2] Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial [J].

Ahren, Bo ;

Masmiquel, Luis ;

Kumar, Harish ;

Sargin, Mehmet ;

Karsbol, Julie Derving ;

Jacobsen, Sanja Hald ;

Chow, Francis .

LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (05) :341-354

[3]

Al-Nozha MM, 2004, SAUDI MED J, V25, P1603

[4]

Alsifri S, 2022, International Journal of Clinical Medicine, V13, P391, DOI [10.4236/ijcm.2022.138027, 10.4236/ijcm.2022.138027, DOI 10.4236/IJCM.2022.138027]

[5]

Alzaid A., 2012, Br J Diabetes Vasc Dis, V12, P57, DOI DOI 10.1177/1474651412444143

[6]

[Anonymous], 2017, IDF Diabetes Atlas, V8th

[7]

[Anonymous], 2022, DIABETES

[8]

[Anonymous], 2012, Guidance regarding methods for de-identification of protected health information in accordance with the Health Insurance Portability and Accountablity Act (HIPAA) Privacy Rule

[9] Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial [J].

Aroda, Vanita R. ;

Bain, Stephen C. ;

Cariou, Bertrand ;

Piletic, Milivoj ;

Rose, Ludger ;

Axelsen, Mads ;

Rowe, Everton ;

DeVries, J. Hans .

LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (05) :355-366

[10] Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making [J].

Berger, Marc L. ;

Sox, Harold ;

Willke, Richard J. ;

Brixner, Diana L. ;

Eichler, Hans-Georg ;

Goettsch, Wim ;

Madigan, David ;

Makady, Amr ;

Schneeweiss, Sebastian ;

Tarricone, Rosanna ;

Wang, Shirley V. ;

Watkins, John ;

Daniel Mullins, C. .

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (09) :1033-1039

← 1 2 3 4 →